In vitro toxicity model: Upgrades to bridge the gap between preclinical and clinical research

Abstract

The Centers for Disease Control and Prevention (CDC) provides extensive data that indicate our need for drugs to maintain human population health. Despite the substantial availability of drugs on the market, many patients lack specific drugs. New drugs are required to tackle this issue. Moreover, we need more reliable models for testing drug toxicity, as too many drug approval failures occur with the current models. This article briefly describes various approaches of the currently used models for toxicity screening, to justify the selection of in vitro cell-based models. Cell-based toxicity models have the best potential to reliably predict drug toxicity in humans, as they are developed using the cells of the target organism. However, currently, a large gap exists between in vitro cell-based approach to toxicity testing and the clinical approach, which may be contributing to drug approval failures. We propose improvements to in vitro cell-based toxicity models, which is often an insight approach, to better match this approach with the clinical homeostatic approach. This should enable a more accurate comparison of data between the preclinical as well as clinical models and provide a more comprehensive understanding of human physiology and biological effects of drugs.

Efficacy and Toxicity Studies of Novel α-MSH Analogues with Antibiofilm Action and β-Lactam Resensitization Potential against MRSA

“…Such contradictory results of in vitro and in vivo toxicity assessments are not unique to this study as it is known that while all of the processes in the human organism are interconnected, in vitro toxicity models mainly focus on biomolecules involved in particular cellular pathways, and such a singular focus on only a specific cell impairment may not be accurate because it neglects the self-repair ability of cells, including the repair mechanisms at the DNA level. 48 Accordingly, as various factors, such as homeostatic imbalance, cell density, cell shape, toxicokinetics, cell viability evaluation methods, end-point, nutrient intake, etc., are major limitations of in vitro cell-based toxicity models, 49 the in vivo acute toxicity assay results (Figure 3B) are a more wholesome and accurate representation of the toxicity of the designed peptides.…”

The Influence of Betulin and Its Derivatives EB5 and ECH147 on the Antioxidant Status of Human Renal Proximal Tubule Epithelial Cells

“…This study showed the different sensitivity of the cells, depending on the species origin. It is vital to choose a proper in vitro model for drug toxicity studies [ 30 ]. The sensitivity of cells may depend on their type and tissue origin.…”

An efficient human stem cells derived cardiotoxicity testing platform for testing oncotherapeutic analogues of quercetin and cinnamic acid

“…The root of the problem is at the cellular level when chemotherapeutic drugs fail to differentiate between normal cells and tumor cells and indiscriminately target the normal cells causing undesired cytotoxicity. Therefore, a representative in vitro toxicity model is needed to understand the difference between target and non-target cells and then predict the possible toxicity 56 .…”